Many brand teams follow the same planning process year after year, but during the pandemic, the parameters have shifted dramatically. How can marketers plan for the future when there are so many unknowns? Read on to find out.
In this POV, market access gurus Mike Motto, Glen Davis, and Peter Weissberg, discuss recent Trump administration action on drug pricing, the likelihood of further action before the 2020 election, and how pharma manufacturers can provide affordable options for more Americans.
Intouch's 2020 class of interns, from disciplines across the agency, shares their thoughts about this unique summer experience, in hopes that they’ll inspire a new cohort of students and recent grads to explore rewarding opportunities at Intouch.
Major national pharmacy chains have announced new options for patients who would like affordable, one-stop, comprehensive healthcare outside of the traditional care setting, as well as new opportunities for PCPs. Three Intouch market access experts offer considerations and opportunities for pharma marketers to navigate this growing retail healthcare delivery trend.
Last week, Fierce Life Sciences hosted a free, three-day virtual version of Digital Pharma Week. Check out some of the key takeaways here.
Some 7,000 different rare diseases affect 25-30 million Americans, but how can pharma marketers find them? Data analytics can help.
There's never a wrong time to consider the importance of marketing to women of color, and what it takes to do it properly. Learn more about how to connect and what you need to do to get it right.
How will COVID-19 affect pharma, and what can pharma marketers do to stay top of mind, while also providing the help searchers need in this uncertain time? Read on to find out.
COVID-19 is accelerating and amplifying healthcare trends, plus creating entirely new ones. In this Intouch POV, we provide strategic and tactical thought-starters for pharma marketers to effectively plan for 2021.
The COVID-19 pandemic has created new opportunities for pharmaceutical manufacturers to enhance their existing payer relationships while also delivering for HCPs and patients faced with navigating their new access and reimbursement realities.
